NCT05868876 - A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

February 28, 2026

Conditions

Advanced Malignant Tumors

Interventions

DRUG

AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion

AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.

Trial Locations (1)

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin